A Prospective, Single-arm, Multicentre Phase II Clinical Study of Arsenic Trioxide in Combination With Chemotherapy and MAPK Pathway Inhibitors for Stage 4/M Neuroblastoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of the combination therapy involving arsenic trioxide, MAPK inhibitors, and chemotherapy for stage 4/M neuroblastoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 18
Healthy Volunteers: f
View:
• Patients with a pathological diagnosis of neuroblastoma.
• Preoperative staging as INRG M stage or postoperative staging as INSS stage 4 (regardless of risk classification).
• Age ≥18 months and ≤18 years.
• Informed consent obtained from the legal guardian, and signed informed consent form.
Locations
Other Locations
China
Sun Yat-sen Memorial Hospital
RECRUITING
Guangzhou
Contact Information
Primary
Yang Li, Professor
drliyang@126.com
86-020-81332456
Time Frame
Start Date: 2025-05-01
Estimated Completion Date: 2031-05-01
Participants
Target number of participants: 92
Treatments
Experimental: Experiment group
Related Therapeutic Areas
Sponsors
Leads: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University